Beijing Darwin Cell Biotechnology Co
Stress-induced stem cell therapies for neurodegenerative diseases
About Beijing Darwin Cell Biotechnology Co
Founded in 2016, Beijing Darwin Cell Biotechnology Co., Ltd. is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) diseases. The company's legal representative is Wang Yu, who also serves as Chairwoman and CEO. Wang was recognized as a "Beijing March 8th Red-Banner Holder" in 2025 for her leadership and scientific achievements.
Darwin Cell Biotechnology leverages proprietary technologies, including stress-induced stem cell technology, to address neural repair in conditions like stroke, Amyotrophic Lateral Sclerosis (ALS), and Alzheimer's disease. The company's core expertise encompasses stem cells, exosomes, and protein polymers. A key development is Aleeto (DEW001), a Class I biological drug designed for CNS diseases, which works by regulating multiple pathways such as inflammation, oxidative stress, and mitochondrial damage to promote neural regeneration. The company's business model revolves around the research, development, and eventual commercialization of these biopharmaceuticals. It collaborates extensively with academic and clinical institutions, such as the joint translational laboratory for ALS and neurorepair established with Beijing Tiantan Hospital and Capital Medical University. Darwin Cell operates three GMP-standard laboratories for R&D, clinical use, and pilot-scale process development, along with subsidiaries for biopharmaceuticals and biomedical consumables.
The company is a venture capital-backed, privately held entity. It has successfully completed multiple funding rounds, including a Series C financing round of over 200 million RMB announced in July 2025. Investors include Taiping Guofa Hehe, Beijing Shijingshan State-owned Asset Management, THG Ventures, and Red Star Macalline.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Dec 2025 | — | — | THG Ventures · Wuhan Optics Valley Financial Holding Group | ↗ |
| SERIES COther financing | Jul 2025 | $28M | $110M | THG Ventures | ↗ |
Growth signals
Latest recorded traffic for Beijing Darwin Cell Biotechnology Co is 740 monthly website visits, down 8.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Darwin Cell Biotechnology Co in the Chaoyang District ecosystem
The Beijing Darwin Cell Biotechnology Co office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- NFNational SME Development Fund
- JIJinan Lantian Investment
- SIShanghai Yungu Investment
- SFShijingshan Modern Innovation Industry Fund
Series B and later2 investors entered at this stage
THG Ventures- WGWuhan Optics Valley Financial Holding Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Darwin Cell Biotechnology Co on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Darwin Cell Biotechnology Co’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








